36 years old. Native German. I work as an equity analyst at a boutique Investment Bank in Europe. I started investing privately in 2001 - just to get burned badly. Got back to investing my private wealth in 2013 with great success so far. I prefer momentum and value strategies. Typically looking for out-of-favour stocks with quality business models. Use fundamental analysis (competitive strategy, defensibility, structural growth potential, valuation, free cash generation) combined with technical analysis for entry/exit points. I am willing to hold high conviction ideas for 1-2 years but will trade in and out of positions depending on news flow and technical indicators (oversold, overbought). I am currently heavily invested into oil and commodities (zinc, copper).
I'm a small investor. As such I focus on the nano to small cap range. As this area generally seems to be under-researched. I'm probably wrong about as often as right in that I fully reserve the right to be very wrong. I'm currently working as a physicist by trade though you'll find no quant articles from me. I consider myself committed to fundamental analysis. The extent of my direct finance background simply consists of the 20 or so credit hours of economics I took back in college. That and managing my (very) small portfolio.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.